drugset / Trial / NCT03622827
Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer
Phase 2
Unknown
120 enrolled
Nanjing Medical University
Second Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of postoperative concurrent chemoradiotherapy combined with recombinant human endostatin (Endostar) in patients with high-risk early stage cervical cancer.
Timeline
- Start
- 2018-07-31
- Primary completion
- 2023-07-30
- Completion
- 2025-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |